hsa-mir-542: Hsa-mir-542 is a microRNA that has been found to have various roles in different types of cancer [PMC3738541]. It has been identified as a non-invasive blood biomarker for tumor monitoring and prognosis prediction in patients with osteosarcoma [32]. In addition, hsa-mir-542 has been shown to target CDK14, inhibiting the development of ovarian cancer [33]. It also inhibits the growth and invasion of colon cancer cells through the PI3K/AKT/survivin signaling pathway [34]. Furthermore, hsa-mir-542 has been found to affect the prognosis of lung adenocarcinoma (LUAD) by inhibiting the expression of TRIM56 [PMC7940991]. Another study found that hsa-mir-542 is negatively correlated with TRIM56 expression and associated with poor prognosis in LUAD patients [PMC7940991]. The overexpression of hsa-mir-542 has also been associated with poor prognosis in LUAD [PMC7940991]. In bladder cancer cells, hsa-mir-542 expression is downregulated and negatively correlated with survivin protein expression, leading to inhibition of proliferation [PMC8907292]. Hsa-mir-542 is identified as a hub microRNA in gene modules related to cancer development and progression [PMC7339803]. Additionally, it has been ranked among other microRNAs as having potential significance in cancer research [PMC3738541].